This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

High-Tech Prostate Cancer Treatments: A Cost Analysis

NEW YORK, Feb. 15, 2013 /PRNewswire/ -- Staying ahead of the curve often comes with a price. In the case of prostate cancer, treatment innovations fuel ongoing debate over the cost-benefit analysis of new technologies and modalities. In an institution-based study led by Dr. David Samadi, Vice Chairman, Department of Urology and Chief of Robotics and Minimally Invasive Surgery at The Mount Sinai Medical Center in New York, Robotic-Assisted Laparoscopic Prostatectomy (RALP) was found to be less than half the cost of radiation.

(Photo: http://photos.prnewswire.com/prnh/20130215/NY61464)

Focused on localized prostate cancer treatments from 2005 to 2009, researchers compared Mount Sinai hospital expenses for open prostate surgery, robotic surgery, brachytherapy seed radiation, Intensity Modulated Radioactive Therapy (IMRT), and a combination of brachytherapy and IMRT. Among the findings presented by Dr. Samadi at the European Association of Urology 27 th Annual Congress in Paris last February, was a savings of more than $8,000 per RALP procedure over IMRT radiation.

Median cost comparison for prostate cancer treatment options:

  • Brachytherapy:  $7,560
  • Robotic prostate removal surgery:  $7,676
  • Open prostate removal surgery:  $8,991
  • Radiation therapy (IMRT):  $15,929
  • Brachytherapy/IMRT combined for high-risk patients: $22,447

"In the past, robotic prostatectomy was regarded as a more expensive prostate cancer treatment. Now we see that may not be the case," said Dr. Samadi. "When we layer these findings with prior research, we fortify the case in favor of robotic prostatectomy," said Dr. Samadi. In September 2012 a comparative results study of radical prostatectomy verses External Beam Radiation Therapy (EBRT) demonstrated an increased survival rate of 40 and 65 percent with RALP. Of the 1,600 localized prostate cancer patients reviewed in the study, two-thirds underwent prostatectomy. http://www.renalandurologynews.com/pca-patient-survival-better-with-rp/article/241954/

Dr. Samadi performs a unique RALP surgery at Mount Sinai coined the Samadi Modified Advanced Robotic Technique (SMART). Having performed more than 4,500 successful robotic prostatectomy procedures, he and his colleagues credit part of the financial savings of surgery to the expertise that comes from their high volume of prostatectomies. Dr. Samadi's SMART procedure reduces surgical time to under two hours, considerably less than those performed at other institutions. Likewise, for most patients, hospital stay is as short as one day.

These figures represent expense to the hospital and not the patient. As such, Dr. Samadi is hopeful that the findings will be instrumental in improving reimbursement decisions regarding prostate cancer surgery, particularly when aligned with successful recovery results. "While the best prostate cancer treatment will always depend on the patient's unique condition, we continue to see documented support for the cost and recovery benefits of RALP," concluded Dr. Samadi.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,122.01 +15.31 0.09%
S&P 500 2,000.12 +0.10 0.00%
NASDAQ 4,569.6210 -1.0160 -0.02%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs